As of April 2026, Kit Roes has been appointed as co-opted member for Biostatistics and Clinical Trial Methodology of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) . The appointment holds for 3 years (renewable).
The CHMP is responsible for conducting the initial assessment of EU-wide marketing authorisation applications for new medicinal products; assessing modifications or extensions to existing marketing authorisations and considering the recommendations of the Agency's Pharmacovigilance Risk Assessment Committee on the safety of medicines.
CHMP's assessments are based on a comprehensive scientific evaluation of data. They determine whether the medicine meets the necessary quality, safety and efficacy requirements and that it has a positive risk-benefit balance.
The appointment is based on Kit Roes’ long term secondment to the Dutch Medicines Evaulation Board (College ter Beoordeling van Geneesmiddelen). In his new role, Kit will directly contribute to regulatory decision making regarding medicines in Europe, with special focus on the methodological soundness of the clinical and statistical evidence.